Phase II Study of Ulixertinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Alterations: APEC1621J of the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial.
Kieuhoa T VoAmit J SabnisP Mickey WilliamsSinchita Roy-ChowdhuriDavid R PattonBrent CoffeyJoel M ReidJin PiaoLauren SaguiligTodd A AlonzoStacey L BergAlok I JajuElizabeth FoxBrenda J WeigelDouglas S HawkinsMargaret M MooneyNaoko TakebeJames V TricoliKatherine A JanewayNita L SeibelDonald Williams ParsonsPublished in: JCO precision oncology (2024)
/dose orally twice a day. Limited single-agent efficacy was observed in a biomarker-selected cohort of refractory pediatric tumors.